Abstract
Cytokeratin 19-derived CYFRA21-1 is an acceptable lung cancer biomarker. However, whether CYFRA21-1 correlates with lung cancer circulating tumor cells (CTCs) remains unclear.
CTCs in 42 lung cancer patients and 10 nonmalignant pulmonary disease patients were isolated by means of an EpCAM-independent enrichment strategy. Correlation of lung cancer CTCs with serum concentration of CYFRA21-1 and pathological staging was investigated.
Among lung cancer patients in this study, 39% (7/18) of those with normal CYFRA21-1 (≤3.3ng/ml) and 62% (13/21) of high CYFRA21-1 (>3.3ng/ml) patients were found to have ≥3 CTCs/7.5ml blood. The CTCs-positive rate of stage I to IV lung cancer patients was 20% (2/10), 45% (5/11), 54% (6/11) and 70% (7/10), respectively. Comparing M0 vs M1 patients, the CTCs-positive rate was 43% (13/30) and 70% (7/10), respectively. All M1 patients (10/10) had one or more CTCs detected, whereas none of the nonmalignant pulmonary disease patients had detectable CTCs.
Lung cancer CTCs isolated by the EpCAM-independent enrichment approach correlate with CYFRA21-1 and TNM staging. Correlation of CTCs and CYFRA21-1 in lung cancer patients is of potential clinical utility in terms of early diagnosis and predicting prognosis.
► CTCs in 42 lung cancer patients were enriched by means of a novel strategy. ► Lung cancer CTCs can be efficiently enriched and detected by this strategy. ► Lung cancer CTCs correlate with TNM staging. ► Elevated serum concentration of CYFRA21-1 correlates with positive CTCs.